Evidence map›Paper›PMID 41185504›Full record

ArticleProtein and peptide letters2025

Aloperine Protects Against Cisplatin-Induced Injury in Kidney Cells

Mingning Qiu, Shuai Zhang, Jinglan Liang, Xuguang Wang, Jie Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Protein and peptide letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingning QiuKey Laboratory of Research in Maternal and Child Medicine and Birth Defects, Guangdong Medical University, Foshan, 528300, Guangdong, China.
Shuai ZhangLaboratory of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong, China.
Jinglan LiangExperimental Animal Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong, China.
Xuguang WangExperimental Animal Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong, China.
Jie LiuKey Laboratory of Research in Maternal and Child Medicine and Birth Defects, Guangdong Medical University, Foshan, 528300, Guangdong, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2020A1515111051, 2022A1515111050Special Foundation for Science and Technology Development of Zhanjiang City, China 2021A05068
6 · The paper itself

Abstract

backgroundAloperine (ALO) is a vital alkaloid present in the traditional Chinese herb Sophora alopecuroides, which has demonstrated effective anti-inflammatory activity. However, the effects and the mechanism of action of ALO on cisplatin (CDDP)-induced nephrotoxicity remain unclear.

objectiveThis study aimed to investigate the effects of ALO on CDDP-induced nephrotoxicity and its potential mechanism of action

methodsCell viability, lactate dehydrogenase cytotoxicity, apoptosis, activity of Caspase-Glo 3/7 and 1, in-cell western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assay (ELISA) were performed to assess the influence of ALO on CDDP-treated kidney cells. Inhibitors of phosphatidylinositol 3-kinase (PI3K, LY294002), protein kinase B (Akt, AKT inhibitor VIII), and nuclear factor kappa B (NFκB, BAY 11-7082) were used to determine their potential mechanisms of action.

resultsThe results indicated that ALO significantly reversed the inhibition of cell viability, cytotoxicity, apoptosis, and the release of inflammatory factors induced by CDDP in kidney cells. ALO attenuated the PI3K/AKT/NFκB-mediated pathway activated by CDDP treatment and downregulated the CDDP-induced nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome. Furthermore, the PI3K and AKT inhibitors diminished the effects of ALO on CDDP-treated kidney cells. Additionally, NFκB inhibitors reversed the effects of the PI3K and AKT inhibitors on ALO in CDDP-treated kidney cells.

conclusionThese results suggest that ALO protects against CDDP-induced injury in kidney cells by modulating the PI3K/AKT/NFκB-mediated NLRP3 inflammasome.

Indexed as

CisplatinInflammasomesKidneyNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinPiperidinesProtective AgentsProto-Oncogene Proteins c-aktAnimalsApoptosisCell LineCell SurvivalPhosphatidylinositol 3-KinasesQuinolizidinesSignal TransductionaloperineCisplatinInflammasomesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinPhosphatidylinositol 3-KinasesPiperidinesProtective AgentsProto-Oncogene Proteins c-aktQuinolizidinesAloperineCDDP-induced injurykidney cellsNLRP3 inflammasomePI3K/AKT/NFκBsophora alopecuroides.

Identifiers

PMID41185504

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.